Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865029 · ClinicalTrials.gov registry record · Phase 2
Estradiol and Progesterone in Hospitalized COVID-19 Patients
A Phase 2 study, sponsored by Tulane University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04865029: Clinical Trial Phase 2 study, sponsored by Tulane University.
NCT04865029 is a Phase 2 study that was terminated before completion, run by Tulane University. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04865029, a Phase 2 study, was terminated before completion, sponsored by Tulane University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to standard of care (SOC) can reduce the severity of symptoms and outcomes compared to SOC alone.
Primary Outcome
The proportion will be calculated based on WHO ordinal scale for clinical improvement. The scale is from 0 to 8, with a higher score indicating worse clinical status. * Uninfected: No clinical or virological evidence of infection 0 * Ambulatory: No limitation of activities 1 Limitation of activities 2 * Hospitalized Mild Disease Hospitalized, no oxygen therapy 3 Oxygen by mask or nasal prongs 4 * Hospitalized Severe Disease Non-invasive ventilation or high flow oxygen 5 Intubation and mechanica
Interventions
- OTHER Placebo injection and placebo pill
- DRUG Estradiol Cypionate 5 mg/ml
- DRUG Progesterone 200 mg Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 2 |
Why NCT04865029 stopped before completion
NCT04865029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo injection and placebo pill is the first listed.
NCT04865029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04865029 about?
NCT04865029 is a clinical study titled "Estradiol and Progesterone in Hospitalized COVID-19 Patients". The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to standard of care (SOC) can reduce the severity of symptoms and outcomes ...
What is the current status of trial NCT04865029?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-07-22. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT04865029?
The interventions under investigation include: Placebo injection and placebo pill (OTHER), Estradiol Cypionate 5 mg/ml (DRUG), Progesterone 200 mg Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT04865029?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04865029's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI